Capitalizing on Extrasynaptic Glutamate Neurotransmission to Treat Antipsychotic-Resistant Symptoms in Schizophrenia

Biological Psychiatry

Volumn 64, Issue 5, 2008, Pages 358-360

  Krystal, John H ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; DEXTRO SERINE; GLUTAMIC ACID; GLYCINE; GLYCINE TRANSPORTER; GLYCINE TRANSPORTER ANTAGONIST; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 3; METABOTROPIC RECEPTOR AGONIST; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; SARCOSINE;

ARTICLE; CLINICAL TRIAL; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; HUMAN; INFORMATION PROCESSING; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; RECEPTOR INTRINSIC ACTIVITY; SCHIZOPHRENIA; SYMPTOM;

EID: 49049087727     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2008.06.011     Document Type: Note

References (26)

1. Krystal J.H., D'Souza D.C., Mathalon D., Perry E., Belger A., and Hoffman R.E. NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: Toward a paradigm shift in medication development. Psychopharmacology 169 (2003) 215-233
2. McCullumsmith R.E., Clinton S.M., and Meador-Woodruff J.H. Schizophrenia as a disorder of neuroplasticity. Int Rev Neurobiol 59 (2004) 19-45
3. Lewis D.A., and Gonzalez-Burgos G. Neuroplasticity of neocortical circuits in schizophrenia. Neuropsychopharmacology 33 (2008) 141-165
4. MacDonald III A.W., and Chafee M.V. Translational and developmental perspective on N-methyl-D-aspartate synaptic deficits in schizophrenia. Dev Psychopathol 18 (2006) 853-876
5. Javitt D.C. Glutamate as a therapeutic target in psychiatric disorders. Mol Psychiatry 9 (2004) 984-997 979
6. Buchanan R.W., Javitt D.C., Marder S.R., Schooler N.R., Gold J.M., McMahon R.P., et al. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): The efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry 164 (2007) 1593-1602
7. Krystal J.H., and D'Souza D.C. D-serine and the therapeutic challenge posed by the N-methyl-D-aspartate antagonist model of schizophrenia. Biol Psychiatry 44 (1998) 1075-1076
8. Patil S.T., Zhang L., Martenyi F., Lowe S.L., Jackson K.A., Andreev B.V., et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: A randomized Phase 2 clinical trial. Nat Med 13 (2007) 1102-1107
9. Moghaddam B., and Adams B.W. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 281 (1998) 1349-1352
10. Krystal J.H., Abi-Saab W., Perry E., D'Souza D.C., Liu N., Gueorgueva R., et al. Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor (mGluR) agonist, LY354740, in healthy human subjects. Psychopharmacology 179 (2005) 303-309
11. Berk M., Copolov D., Dean O., Lu K., Jeavons S., Schapkaitz I., et al. N-acetyl cysteine as a glutathione precursor for schizophrenia-a double-blind, randomized, placebo-controlled trial. Biol Psychiatry 64 (2008) 361-368
12. Lavoie S., Murray M.M., Deppen P., Knyazeva M.G., Berk M., Boulat O., et al. Glutathione precursor, n-acetyl-cysteine, improves mismatch negativity in schizophrenia patients. Neuropsychopharmacology 33 (2007) 2187-2199
13. Braun I., Genius J., Grunze H., Bender A., Moller H.J., and Rujescu D. Alterations of hippocampal and prefrontal GABAergic interneurons in an animal model of psychosis induced by NMDA receptor antagonism. Schizophr Res 97 (2007) 254-263
14. Abekawa T., Ito K., Nakagawa S., and Koyama T. Prenatal exposure to an NMDA receptor antagonist, MK-801 reduces density of parvalbumin-immunoreactive GABAergic neurons in the medial prefrontal cortex and enhances phencyclidine-induced hyperlocomotion but not behavioral sensitization to methamphetamine in postpubertal rats. Psychopharmacology (Berl) 192 (2007) 303-316
15. Wang C.Z., Yang S.F., Xia Y., and Johnson K.M. Postnatal phencyclidine administration selectively reduces adult cortical parvalbumin-containing interneurons. [published online ahead of print December 5]. Neuropsychopharmacology (2007)
16. Cunningham M.O., Hunt J., Middleton S., LeBeau F.E., Gillies M.J., Davies C.H., et al. Region-specific reduction in entorhinal gamma oscillations and parvalbumin-immunoreactive neurons in animal models of psychiatric illness. J Neurosci 26 (2006) 2767-2776
17. Schoepp D.D. Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system. J Pharmacol Exp Ther 299 (2001) 12-20
18. Woolley M.L., Pemberton D.J., Bate S., Corti C., and Jones D.N. The mGlu2 but not the mGlu3 receptor mediates the actions of the mGluR2/3 agonist, LY379268, in mouse models predictive of antipsychotic activity. Psychopharmacology (Berl) 196 (2008) 431-440
19. Tamaru Y., Nomura S., Mizuno N., and Shigemoto R. Distribution of metabotropic glutamate receptor mGluR3 in the mouse CNS: Differential location relative to pre- and postsynaptic sites. Neuroscience 106 (2001) 481-503
20. Lujan R., Roberts J.D., Shigemoto R., Ohishi H., and Somogyi P. Differential plasma membrane distribution of metabotropic glutamate receptors mGluR1 alpha, mGluR2 and mGluR5, relative to neurotransmitter release sites. J Chem Neuroanat 13 (1997) 219-241
21. Do K.Q., Trabesinger A.H., Kirsten-Kruger M., Lauer C.J., Dydak U., Hell D., et al. Schizophrenia: Glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. Eur J Neurosci 12 (2000) 3721-3728
22. Baker D.A., Xi Z.X., Shen H., Swanson C.J., and Kalivas P.W. The origin and neuronal function of in vivo nonsynaptic glutamate. J Neurosci 22 (2002) 9134-9141
23. Baker D.A., Madayag A., Kristiansen L.V., Meador-Woodruff J.H., Haroutunian V., and Raju I. Contribution of cystine-glutamate antiporters to the psychotomimetic effects of phencyclidine. Neuropsychopharmacology 33 (2008) 1760-1772
24. Sokolov B.P. Oligodendroglial abnormalities in schizophrenia, mood disorders and substance abuse. Comorbidity, shared traits, or molecular phenocopies?. Int J Neuropsychopharmacol 10 (2007) 547-555
25. Segal D., Koschnick J.R., Slegers L.H., and Hof P.R. Oligodendrocyte pathophysiology: A new view of schizophrenia. Int J Neuropsychopharmacol 10 (2007) 503-511
26. Hardingham G.E., Fukunaga Y., and Bading H. Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat Neurosci 5 (2002) 405-414